Investors' Chronicle cover image

How to pass on wealth, AstraZeneca & Ceres: The Companies and Markets Show

Investors' Chronicle

00:00

Valuation contrast: GSK for income, Astra for growth

Julian contrasts GSK's income appeal with AstraZeneca's growth premium and future US strategy pressures.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app